Salute e Benessere

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over…

Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five...
Nasdaq GlobeNewswire
30/04/2025

Press Release: Annual General Meeting of April 30, 2025

Annual General Meeting of April 30, 2025Approval of the financial statements for the fiscal year 2024Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul KressParis, April 30, 2025. The Combined General Shareholders' Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by...
Nasdaq GlobeNewswire
30/04/2025

Interim Report Q1 2025: Growth challenged by market uncertainty – proactive cost…

HighlightsThe Hearing division delivered -1% organic revenue growth driven by a strong initial uptake of ReSound Vivia, but off-set by a challenged U.S. market as well as some slowdown of existing products in anticipation of ReSound Vivia. The strong uptake of ReSound Vivia has continued into April, lending support for expected market share gains. As a consequence of the launch initiatives and the challenged U.S. market, the divisional profit margin ended at 28.4%.The Enterprise...
Nasdaq GlobeNewswire
30/04/2025

Ipsen S.A. - Formalities for making available and consulting preparatory…

Information relating to the holding of the Combined Shareholders' Meeting of 21 May 2025 of Ipsen S.A.Formalities for making available and consulting preparatory documents to the Meeting PARIS, FRANCE, 30 April 2025 -Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Shareholders of the Company are invited to participate in the Combined Shareholders' Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Wednesday 21 May 2025 at 3:00 p.m. (Paris time) at...
Nasdaq GlobeNewswire
30/04/2025

EssilorLuxottica: EssilorLuxottica 2025 Annual Shareholders' Meeting

EssilorLuxottica 2025 Annual Shareholders' Meeting All resolutions proposed by the Board of Directors adoptedDividend of Euro 3.95 per share, with option for payment in shares Paris, France (30 April 2025–6:00 pm CEST)– EssilorLuxottica Annual Shareholders' Meeting was held today at 3 Mazarium in Paris. Shareholders approved all 17 resolutions submitted by the Board of Directors to the Ordinary and Extraordinary General Meeting, including the distribution of a Euro 3...
Nasdaq GlobeNewswire
30/04/2025

Eyewear Market to be worth $335.90 Billion by 2030 at CAGR 8.6% - Grand View…

The growing awareness of eye health initiatives by government organizations is playing a significant role in driving the growth of the market. Governments worldwide are implementing programs and campaigns to educate the public about the importance of regular eye exams, early detection of eye conditions, and the use of appropriate eyewear. These initiatives are raising awareness about the potential consequences of neglecting eye health, encouraging individuals to seek professional care, and…
PR Newswire
30/04/2025

Mise à disposition du rapport financier annuel 2024

Communiqué de presseMise à dispositiondu rapport financier annuel 2024Dijon, France le 30 avril 2025 (17h45 CET) --CROSSJECT(ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique spécialisée en phase avancée de développement et d'enregistrement de ZEPIZURE®, sa solution d'urgence pour la gestion des crises d'épilepsie, annonce avoir mis à la disposition du public et déposé auprès de l'Autorité des Marchés Financiers son rapport financier annuel 2024. Le rapport...
Nasdaq GlobeNewswire
30/04/2025

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the…

Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company's 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company's website under Investors/Shareholder Meetings.The Board of Directors has decided to nominate Dr...
Nasdaq GlobeNewswire
30/04/2025

ONWARD Medical Convocation of the 2025 Annual General Meeting of Shareholders…

The resolutions proposed by the Board, to be submitted for adoption at the AGM, are as follows: Adoption of the annual accounts over the financial year 2024 (voting item)Implementation of the compensation policy over the financial year 2024 (advisory non-binding voting item)Approval of the compensation policy for the board (voting item)Release of the directors from liability for the exercise of their duties during the financial year 2024 (voting item)Instruction of Ernst...
Nasdaq GlobeNewswire
30/04/2025

Guidance updated: Impact from and mitigation to navigate the global trade…

Following the recent announcements by the U.S. administration regarding tariffs, GN now takes further actions to counter the negative direct and indirect effects from the increased tariff levels. With the actions, GN is capable of mitigating the majority of the assumed tariff impact on the EBITA margin in 2025 as well as protecting its mid-term earnings growth. The development in tariffs and its impact on our markets makes our environment more uncertain than normal. As a base assumption...
Nasdaq GlobeNewswire
30/04/2025

ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer…

"The future of healthcare is in the data. At ZEISS, we are delivering digital innovation to help shape the future of ophthalmology, investing in research methods that empower clinicians and researchers in balancing their clinical care and research requirements," says Euan S. Thomson, Ph.D., Head of the Digital Business Unit for ZEISS Medical Technology. "The introduction of the ZEISS RDP reflects our commitment to advancing ophthalmic care through smarter, AI-powered tools."…
PR Newswire
30/04/2025

Novartis to acquire Regulus Therapeutics and farabursen, an investigational…

Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal diseaseLead asset for ADPKD, farabursen, is a novel, next-generation oligonucleotide targeting miR-17 that recently completed a Phase 1b multiple-ascending dose clinical trial Transaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a future...
Nasdaq GlobeNewswire
30/04/2025

New Survey Provides Insights into Diagnosis and Treatment Journey for People…

DUBLIN, April 30, 2025 /PRNewswire/ -- A new online survey conducted by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), sought to understand utilization of and experiences with treatment among 300 adults between ages 21-64 who self-identify as having been diagnosed with alcohol use disorder (AUD) by a healthcare provider. The survey showed that the path to AUD diagnosis can be challenging and often driven by negative consequences, but treatment may…
PR Newswire
30/04/2025

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod…

Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans to analyze the efficacy data from the 17 patients who have now completed the Phase 2 trial.OKYO Pharma plans for a meeting with FDA following evaluation of clinical data.LONDON and NEW YORK, April30, 2025(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused...
Nasdaq GlobeNewswire
30/04/2025

Press Release: Sanofi and CD&R close Opella transaction, create global consumer…

Sanofi and CD&R close Opella transaction, create global consumer healthcare leaderParis, April 30, 2025 .Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake. Bpifrance will own a 1.8% stake in Opella and will...
Nasdaq GlobeNewswire
30/04/2025

Gedeon Richter: Medical Treatment of Endometriosis with a progressive approach

Historically, surgical interventions were the primary option for managing endometriosis. Today, however, medical therapy is becoming the preferred treatment option, with its less invasive, sustainable and effective long-term outcomes. Hormonal treatments aim to reduce estrogen levels, which in turn slows the growth of endometrial-like tissue. Clinical studies show that more than 70% of women treated with hormonal therapies experience significant pain reduction and improved quality of life. ...
PR Newswire
30/04/2025

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate…

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateContinuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson's disease (PD)Additional ACI-7104.056 Phase 2 interim results (pharmacodynamics and biomarkers) expected in Q2 2025...
Nasdaq GlobeNewswire
30/04/2025

MolecuLight Unveils Thermal Imaging for DX™ Platform, Delivering Measurement…

MolecuLight is making a strong statement at the SAWC Spring meeting with over 10 posters demonstrating the transformative power of their fluorescence imaging, thermal imaging, and wound measurement technology. These presentations delve into key themes such as: enhancing wound assessment through precise bacterial detection and healing progress monitoring, revolutionizing the management of complex surgical wound reconstructions, and pioneering a holistic evaluation approach by integrating…
PR Newswire
30/04/2025

Teka begins a New Century as part of Midea Group

Teka Group will enhance its operations, expand its product lines, and enter new categories with the assistance of Midea. The transaction will allow to reinforce the organizational structure and three iconic trademarks of Teka Group: Teka, Küppersbusch, and Intra, while leveraging Midea's global operations and R&D capabilities to unlock synergies. Teka Group will enhance its operations, expand its product lines, and enter new categories with the assistance of Midea. The transaction will allow…
PR Newswire
30/04/2025

DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care

Recognized for Advancing Global Wound Care Through Innovation and Efficacy IIWCG Achievement Award 2025forInnovation in Wound Careat the16th Abu Dhabi Wound Care Conference.Media Snippet.Presented during the Opening Ceremony at ADNEC, this recognition by theInternational Interprofessional Wound Care Group (IIWCG)honors excellence in wound care and spotlights breakthroughs redefining standards in chronic wound management through innovation and efficacy.It is not only...
Nasdaq GlobeNewswire
30/04/2025

Notice of Annual General Meeting 2025

The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate websitewww.pcibiotech.com.For further information, please contact:Ronny Skuggedal, CEO/CFO, E-mail: [email protected] Office: +47 67 11 54 00 Mobile: +47 94 00 57 57This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments PCI Biotech...
Nasdaq GlobeNewswire
30/04/2025

Sampled Obtains Wholesale Distribution Authorisation (WDA) Licensing, Expanding…

WDA licensing, regulated by the MHRA, is mandatory for any organisation that stores or distributes human or veterinary medicines in the UK. This license ensures compliance with strict regulations, requiring that medicinal products are handled safely and maintained to high quality standards. WDA ensures customer protection by safeguarding end users from counterfeit products. It also mandates thorough documentation, which must be accurately maintained and stored for a minimum of ten years. WDA...
PR Newswire
30/04/2025

BANILA CO Dominates the Global Cleansing Balm Market, Ranked No.1 Top Selling…

SEOUL, South Korea, April 30, 2025 /PRNewswire/ -- Makeup brand Banila Co announced that it has been named the world's top-selling cleansing balm brand[1], based on retail sales data compiled, according to data analytics company Euromonitor International. SEOUL, South Korea , April 30, 2025 /PRNewswire/ -- Makeup brand Banila Co announced that it has been named the world's top-selling cleansing balm brand [1], based on retail sales data compiled, according to data analytics company...
PR Newswire
30/04/2025

Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at…

Poster presentation #7450 titled "Clinical PK, PD and safety analysis of a phase I clinical trial of DT-9081, an EP4R-antagonist, for RP2D determination in patients with advanced solid tumors", details Phase I clinical trial results for DT-9081, a novel EP4 receptor antagonist. The findings outline DT-9081's promising potential to inhibit tumor growth and enhance immune response in patients with advanced solid tumors. Administered orally once daily, DT-9081 has demonstrated: Poster…
PR Newswire
30/04/2025
Altri  Comunicati